Development of targeted alpha particle therapy for solid tumors

NK Tafreshi, ML Doligalski, CJ Tichacek, DN Pandya… - Molecules, 2019 - mdpi.com
Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-
particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or …

Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade

RB Patel, R Hernandez, P Carlson… - Science translational …, 2021 - science.org
Molecular and cellular effects of radiotherapy on tumor microenvironment (TME) can help
prime and propagate antitumor immunity. We hypothesized that delivering radiation to all …

The radiobiology of radiopharmaceuticals

ZS Morris, AZ Wang, SJ Knox - Seminars in radiation oncology, 2021 - Elsevier
Radiopharmaceutical therapy or targeted radionuclide therapy (TRT) is a well-established
class of cancer therapeutics that includes a growing number of FDA-approved drugs and a …

ICRU REPORT 96, dosimetry-guided radiopharmaceutical therapy

G Sgouros, WE Bolch, A Chiti… - Journal of the …, 2021 - journals.sagepub.com
The International Commission on Radiation Units and Measurements (ICRU), since its
inception in 1925, has had as its principal objective the development of internationally …

Whole-body voxel-based internal dosimetry using deep learning

A Akhavanallaf, I Shiri, H Arabi, H Zaidi - European Journal of Nuclear …, 2021 - Springer
Purpose In the era of precision medicine, patient-specific dose calculation using Monte
Carlo (MC) simulations is deemed the gold standard technique for risk-benefit analysis of …

[HTML][HTML] Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy

JC Jagodinsky, WJ Jin, AM Bates, R Hernandez… - Theranostics, 2021 - ncbi.nlm.nih.gov
Rationale: Clinical interest in combining targeted radionuclide therapies (TRT) with
immunotherapies is growing. External beam radiation therapy (EBRT) activates a type 1 …

Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative …

K Magee, IR Marsh, MM Turek, J Grudzinski… - PLoS …, 2021 - journals.plos.org
Rationale Murine syngeneic tumor models have revealed efficacious systemic antitumor
responses following primary tumor in situ vaccination combined with targeted radionuclide …

Quantitative SPECT/CT for dosimetry of peptide receptor radionuclide therapy

J Kennedy, A Chicheportiche, Z Keidar - Seminars in nuclear medicine, 2022 - Elsevier
Neuroendocrine tumors (NETs) are uncommon malignancies of increasing incidence and
prevalence. As these slow growing tumors usually overexpress somatostatin receptors …

What you see is not what you get: on the accuracy of voxel-based dosimetry in molecular radiotherapy

J Tran-Gia, M Salas-Ramirez… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Improvements in quantitative SPECT/CT have aroused growing interest in voxel-based
dosimetry for radionuclide therapies, because it promises visualization of absorbed doses at …

[HTML][HTML] Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors

HK Potluri, CA Ferreira, J Grudzinski… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Systemic radiation treatments that preferentially irradiate cancer cells over
normal tissue, known as targeted radionuclide therapy (TRT), have shown significant …